Evidence map›Paper›PMID 42640436›Full record

ArticleAdvances in therapy2026

Development of a Claims-Based Algorithm and Validation Through Medical Chart Review to Identify Patients with Crohn's Disease-Related Fibrostenosis: A Retrospective Observational Study in the United States.

Yiran Zhang, William K Mountford, Jennifer Thompson, Ling Zhang, Maureen Carlyle, John White, Valery Walker, Florian Rieder

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yiran ZhangValue and Evidence Solutions, Optum, Eden Prairie, Minnesota, USA.
William K MountfordBoehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
Jennifer ThompsonBoehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
Ling ZhangBoehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
Maureen CarlyleValue and Evidence Solutions, Optum, Eden Prairie, Minnesota, USA.
John WhiteValue and Evidence Solutions, Optum, Eden Prairie, Minnesota, USA.
Valery WalkerValue and Evidence Solutions, Optum, Eden Prairie, Minnesota, USA.
Florian RiederDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Ave. NC2, Cleveland, Ohio, 44195, USA. riederf@ccf.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFibrostenosis is a prevalent and clinically burdensome complication of Crohn's disease (CD), which is a type of inflammatory bowel disease. Identifying CD-related fibrostenosis (fsCD) in large datasets is challenging due to a lack of specific diagnostic codes. Manual chart review is the current standard, but it is not scalable for broader research. The objective of this study was the development and validation of a claims-based algorithm to identify patients with fsCD and improve understanding of its progression and healthcare impact.

methodsA classification algorithm was developed to identify fsCD cases within a large administrative claims database in the United States and was subsequently validated through medical chart review. A logistic model analyzed claims-based evidence of disease-related events that could be used to identify presumptive cases. Bootstrapping was used for internal validation of the model results. Chart abstraction captured specific clinical characteristics, based on clinician-endorsed criteria, as evidence of the disease.

resultsThe final algorithm consisted of two components that individually or collectively identified fsCD: (1) a diagnosis of CD-related intestinal obstruction, defined as ≥ 2 non-diagnostic medical claims on separate dates; and (2) a regression-based probability score derived from the logistic model. Of the 18,609 patients included in the algorithm development, 300 presumptive cases and 300 presumptive controls were selected as the validation cohort and compared against medical charts; 216 cases and 277 controls were identified correctly. Applied to the full cohort (n = 18,609), the algorithm yielded a weighted positive predictive value, weighted negative predictive value, weighted sensitivity, and weighted specificity of 72.00%, 92.33%, 70.20%, and 92.93%, respectively.

conclusionThe current study presents a validated, claims-based algorithm with a robust predictive functionality to identify patients with fsCD. The algorithm provides a scalable tool using real-world data and may facilitate future studies on the disease´s epidemiology, clinical outcomes, and healthcare burden. Graphical abstract available for this article https://doi.org/10.6084/m9.figshare.32909042 .

Indexed as

Administrative health dataClaims-based algorithmCrohn’s diseaseFibrostenosisStrictures

Identifiers

PMID42640436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.